跳至主要内容
临床试验/EUCTR2009-010759-29-BE
EUCTR2009-010759-29-BE进行中(未招募)1 期

étude clinique sur l’administration de 3 doses de betaméthasone (12mg) à 18 heures d’intervalle lors d’une menace d’accouchement prématuré dans les grossesses gémellaires traitées par Atosiban, plutôt que 2 doses de betaméthasone (12mg) à 24 heures d’intervalle; afin de diminuer le risque de syndrome de détresse respiratoire chez les nouveau-nés . - CORTGEM

Cliniques Universitaires Saint-Luc0 个研究点目标入组 50 人开始时间: 2009年3月30日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • 1. sign inform consent
  • 2. normal twin pregnancy
  • 3. mother's age between 18 and 40 years old
  • 4. premature delivery risk based on the cardiotocography analysis (> 6 contractions / 30 minutes) with open cervix (> 1 cm) on digital examination and/or ultrasound cervical length < 25 mm
  • 5. treatment with atosiban
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years)
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. medical contra-indication for tocolysis (mother or fetus)
  • 2. fetal distress based on the cardiotocography and/or ultrasouind
  • 3. Contra-indication to corticoïd (infection)
  • 4. Other treatment with corticoïd (local or general)
  • 5. Previous administration of corticoïds for lung maturation in this pregnancy
  • 6. Diabetes melitus with insuline therapy

研究者

相似试验

进行中(未招募)
1 期
Clinical trial of a new protocol of lung maturation by administration of corticoids in twin pregnancy patients with threatened preterm birth treated by Atosiban : administration of 3 doses of betamethasone (12 mg) in 18 hours apart, rather than 2 doses of betamethasone (12 mg) in 24 hours apart as used usually, to decrease the risk of respiratory distress syndrome at the newborn childrePremature delivery in twin pregnanciesMedDRA version: 19.1Level: LLTClassification code 10028244Term: Multiple pregnancy affecting fetus or newbornSystem Organ Class: 100000004868MedDRA version: 19.1Level: LLTClassification code 10036564Term: Pregnancy multipleSystem Organ Class: 100000004868
EUCTR2016-003603-61-BE50
尚未招募
4 期
The Role of Triphala Rasayana Regimen in Dyslipidaemia (-Medhodushti)
CTRI/2023/02/049545Ch.Brahm prakash Ayurved charak Sansthan.
进行中(未招募)
1 期
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 19.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disorders
EUCTR2016-000685-39-FRovo Nordisk A/S372
进行中(未招募)
1 期
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 19.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disorders
EUCTR2016-000685-39-FIovo Nordisk A/S372
进行中(未招募)
1 期
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 20.1Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disorders
EUCTR2016-000685-39-DKovo Nordisk A/S288